

BEST AVAILABLE COPY**REMARKS**

Through this Amendment, claims 1-2, 5 and 18-21 have been amended to more clearly point out and distinctly claim the invention. After these amendments are entered, twenty two (23) claims (1-8 and 15-29) remain pending in this application.

Information Disclosure Statement

The foreign reference FR 2582416 is related to a bifocal contact lens having a truncated bottom (low edge) and thinner top edge. As summarize by the Abstract of FR 2582416, the bifocal contact lens disclosed in FR 2582416 has a first surface or internal surface 1, a second surface or external surface 2, a first part 4 being adapted for distance vision, a second part 5 being adapted for near vision, wherein the first surface is spherical surface and centered around the optical axis of the lens, wherein the second part is disposed mostly below the first part, wherein the lens has a circular peripheral border except that the inferior part of the peripheral border is truncated to form a horizontal sensible border 6, wherein the second surface is also centered around the optical axis and has a part 7 having smaller thickness in a superior region above the first part 4 for the distance vision.

Claim Objections


Claims 2, 5 and 18-21 have been amended to overcome the objections set forth in the Office Action.

Claim Rejections – 35 U.S.C §103

Claim 1 was rejected under 35 U.S.C. §103(a) as being unpatentable over Volker et al. This rejection is moot in view of the amendment of claim 1, which now depends on claims. Applicants respectfully request withdrawal of the 35 U.S.C. §103(a) rejection.

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned. Please address all correspondence to Thomas Hoxie, Novartis Corporation, Corporate Intellectual Property, One Health Plaza, Bldg. 430, East Hanover, NJ 07936-1080. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 19-0134.

Respectfully submitted,


Jian S. Zhou
Reg. No. 41,422
(678) 415-4691

Date: 12/11/2003

Novartis Corporation
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080